BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Rare diseases

  AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study

  AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to the current enzyme replacement therapy standard.

  February 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Infectious disease

  AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance

  The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.

  February 10, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Immunology and inflammation

  Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study

  It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF study in idiopathic pulmonary fibrosis.

  February 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win

  Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary fibrosis—nearly six months after achieving a similar feat in idiopathic pulmonary fibrosis. Boehringer plans to submit for FDA and other global approvals in both indications.

  February 10, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Mergers & acquisitions

  Bain Bets Big on Japanese Market With $3.3B Tanabe Buy

  The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences market, recently revitalized by more industry-friendly policy changes from the government.

  February 10, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Lymphoma

  BMS Positions Breyanzi for Another Indication as LOE Woes Mount

  Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the coming years.
  

  February 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference

  February 10, 2025

   · 

  3 min read
• Press Releases

  Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

  February 10, 2025

   · 

  10 min read
• Press Releases

  Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

  February 10, 2025

   · 

  14 min read
• Press Releases

  Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America

  February 10, 2025

   · 

  6 min read